Data on the Anti-inflammatory Activity of Cempra Pharmaceutical's CEM-101 Will be Presented at the American Thoracic Society 2010 International Conference
Both posters will be presented during the poster session entitled "C41 Emerging Pharmacology for Chronic Obstructive Pulmonary Disease: Mechanisms and Outcomes" scheduled for 8:15 a.m. to 4:00 p.m. CDT on Tuesday, May 18.
Cempra Pharmaceuticals ATS 2010 International Conference Schedule At-A-Glance
Tuesday, May 18, 2010
CEM-101 is a next generation macrolide with a number of attributes that may provide clinically important advantages over several comparator products:
The annual incidence for pneumonia in the United States is over 5 million patients each year. There is a growing need for new drugs to address the issues of drug resistance, tolerability, and administration associated with currently available treatments. Cempra has licensed exclusive worldwide rights from Optimer Pharmaceuticals, Inc., except in the Association of Southeast Asian Nations (ASEAN) countries, to discover, develop and commercialize macrolides from a library of more than 500 compounds from Optimer's OPopS drug discovery platform.
About Cempra Pharmaceuticals
Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially and medically differentiated and novel products that reduce development risk and provide a high financial return. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.
-- Poster Presentation: "A novel macrolide/ fluoroketolide, CEM-101, reverses corticosteroid insensitivity under oxidative stress, via PI3K pathway inhibition" Time: On display: 8:15 a.m. to 4:00 p.m. CDT, Poster # 3527 Location: F62, Area F, Hall G Y. Kobayashi, C. Rossios, D. Takagi, P.J. Barnes, K. Ito (Airway Disease Section, NHLI, Imperial College London, UK) -- Poster Presentation: "Superior anti-inflammatory effects of a novel macrolide/fluoroketolide, CEM-101 in monocytic cells" Time: On display: 8:15 a.m. to 4:00 p.m. CDT, Poster # 3506 Location: F63, Area F, Hall G Y. Kobayashi, C. Rossios, P.J. Barnes, K. Ito (Airway Disease Section, NHLI, Imperial College London, UK)
SOURCE Cempra Pharmaceuticals
You May Also Like